Evidence map›Paper›PMID 41147126›Full record

Observational studyInternational journal of methods in psychiatric research2025

Diagnostic and Predictive Utility of Plasma Phosphoethanolamine Levels in Depressive Disorder: A Naturalistic Observational Study.

Noriyuki Kawamura, Akinori Nakata, Tsuyoto Harada, Yoshiaki Ohashi, Hajime Sato, Kazunori Sasaki, Shoichiro Tsugane

Abstract readObservational Study
In one paragraph

Observational study in International journal of methods in psychiatric research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Noriyuki KawamuraKawamura Clinic for General Practice, Gyouki-Kai Medical Corporation, Tokyo, Japan.ORCID 0000-0001-5212-0213
Akinori NakataDepartment of Preventive Medicine and Community Health, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan.
Tsuyoto HaradaKawamura Clinic for General Practice, Gyouki-Kai Medical Corporation, Tokyo, Japan.
Yoshiaki OhashiHuman Metabolome Technologies Inc., Tsuruoka, Japan.
Hajime SatoHuman Metabolome Technologies Inc., Tsuruoka, Japan.
Kazunori SasakiHuman Metabolome Technologies Inc., Tsuruoka, Japan.
Shoichiro TsuganeGraduate School of Public Health, International University of Health and Welfare, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesPlasma phosphoethanolamine (PEA) has been proposed as a potential biomarker for depressive disorder. To further assess its diagnostic utility and relevance across psychiatric conditions, we conducted a larger observational study in a psychiatric primary care setting.

methodsBetween 2013 and 2020, 576 patients underwent DSM-5-based psychiatric assessments. Plasma PEA levels were measured in 295 patients with depressive disorders, 264 with other psychiatric disorders, and 17 with physical illnesses.

resultsPEA demonstrated moderate or high diagnostic accuracy for depressive disorder (AUC = 0.81, 95% CI: 0.78-0.85). Lower PEA levels were significantly associated with depression (OR = 16.30, p < 0.001).

conclusionsThese findings suggest that plasma PEA concentration may serve as a useful biomarker for depressive disorder. Further studies are warranted to explore its potential relationship with white matter pathology in psychiatric conditions.

Indexed as

Depressive DisorderEthanolaminesAdultAgedBiomarkersFemaleHumansMaleMiddle AgedBiomarkersEthanolaminesphosphorylethanolaminedepressive disorderdiagnostic biomarkerplasma phosphoethanolamine concentrations

Identifiers

PMID41147126
PMCPMC12559855

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.